Welcome to our dedicated page for Werewolf Therapeutics news (Ticker: HOWL), a resource for investors and traders seeking the latest updates and insights on Werewolf Therapeutics stock.
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) is a clinical-stage biopharmaceutical company pioneering conditionally activated immunotherapies for cancer treatment. This news hub provides investors and industry observers with essential updates on the company’s innovative pipeline, including its INDUKINE molecules WTX-330 and WTX-124 developed through the proprietary PREDATOR platform.
Access real-time announcements covering clinical trial progress, regulatory milestones, financial results, and strategic partnerships. Our curated collection ensures you stay informed about developments in immuno-oncology therapies designed to activate only within tumor microenvironments – a breakthrough approach aiming to improve safety profiles compared to traditional cytokine treatments.
Key updates include phase 1/2 trial data readouts, IND applications, collaboration agreements, and peer-reviewed research publications. All content is vetted for relevance to investment analysis and therapeutic advancement in solid tumors and immune-mediated diseases.
Bookmark this page for streamlined tracking of HOWL’s scientific and corporate developments. Combine our news feed with Stock Titan’s financial tools to monitor this innovator’s progress in redefining cancer immunotherapy.
Werewolf Therapeutics announced the presentation of updated clinical data from its Phase 1/1b trial of WTX-124, both as monotherapy and in combination with pembrolizumab, at the 2024 ASCO Annual Meeting. The data, current as of January 28, 2024, and updated until May 1, 2024, shows that WTX-124 is well-tolerated and clinically active in patients with advanced or metastatic solid tumors who have relapsed after checkpoint inhibitor therapy.
Preliminary combination data with pembrolizumab indicates similar tolerability to monotherapy. Werewolf will host a webcast on June 3, 2024, to discuss the results in detail. This Phase 1/1b trial is evaluating the IL-2 INDUKINE™ molecule, aiming to address unmet medical needs in difficult-to-treat cancers.
Werewolf Therapeutics, Inc. reports Q1 2024 financial results and business update. The company focuses on WTX-124 and WTX-330 clinical trials, with promising data expected. They showcase the PREDATOR platform potential in immunology-based diseases. Werewolf extends its cash runway till Q1 2026. Recent achievements include FDA alignment on a manufacturing process and entering a funding agreement with K2 HealthVentures. Financially, the company maintains a solid cash position, with collaboration revenue and R&D expenses on track.
FAQ
What is the current stock price of Werewolf Therapeutics (HOWL)?
What is the market cap of Werewolf Therapeutics (HOWL)?
